Drug Type Biosimilar, Monoclonal antibody |
Synonyms Golimumab Biosimilar (JAMP Pharma Corp.), 戈利木单抗生物类似药(JAMP Pharma Corp.) |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |








| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Arthritis | NDA/BLA | Canada | 01 Jun 2025 |






